{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T02:21:57Z","timestamp":1773282117605,"version":"3.50.1"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2005,7,1]],"date-time":"2005-07-01T00:00:00Z","timestamp":1120176000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2005,7,1]],"date-time":"2005-07-01T00:00:00Z","timestamp":1120176000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr Allergy Asthma Rep"],"published-print":{"date-parts":[[2005,7]]},"DOI":"10.1007\/s11882-005-0077-x","type":"journal-article","created":{"date-parts":[[2007,6,3]],"date-time":"2007-06-03T01:24:15Z","timestamp":1180833855000},"page":"327-332","source":"Crossref","is-referenced-by-count":21,"title":["Recent advances in the management of ocular complications of sj\u00f6gren\u2019s syndrome"],"prefix":"10.1007","volume":"5","author":[{"given":"Michael","family":"Samarkos","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haralampos M.","family":"Moutsopoulos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"77_CR1","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1001\/archinte.164.12.1275","volume":"164","author":"SS Kassan","year":"2004","unstructured":"Kassan SS, Moutsopoulos HM: Clinical manifestations and early diagnosis of Sjogren syndrome. Arch Intern Med 2004, 164:1275\u20131284.","journal-title":"Arch Intern Med"},{"key":"77_CR2","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1111\/j.1741-2358.2002.00053.x","volume":"19","author":"J Rostron","year":"2002","unstructured":"Rostron J, Rogers S, Longman L, et al.: Health-related quality of life in patients with primary Sjogren\u2019s syndrome and xerostomia: a comparative study. Gerodontology 2002, 19:53\u201359.","journal-title":"Gerodontology"},{"key":"77_CR3","first-page":"63","volume":"25","author":"N Sutcliffe","year":"1998","unstructured":"Sutcliffe N, Stoll T, Pyke S, Isenberg DA: Functional disability and end organ damage in patients with systemic lupus erythematosus (SLE), SLE and Sjogren\u2019s syndrome (SS), and primary SS. J Rheumatol 1998, 25:63\u201368.","journal-title":"J Rheumatol"},{"key":"77_CR4","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1097\/01.ico.0000134183.47687.75","volume":"23","author":"P Reddy","year":"2004","unstructured":"Reddy P, Rajagopalan K: The economic burden of dry eye. Cornea 2004, 23:751\u2013761.","journal-title":"Cornea"},{"key":"77_CR5","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1007\/s002810100070","volume":"23","author":"NM Moutsopoulos","year":"2001","unstructured":"Moutsopoulos NM, Moutsopoulos HM: Therapy of Sjogren\u2019s syndrome. Springer Semin Immunopathol 2001, 23:131\u2013145.","journal-title":"Springer Semin Immunopathol"},{"key":"77_CR6","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1097\/00003226-200009000-00009","volume":"19","author":"SC Pflugfelder","year":"2000","unstructured":"Pflugfelder SC, Solomon A, Stern ME: The diagnosis and management of dry eye: a twenty-five-year review. Cornea 2000, 19:644\u2013649.","journal-title":"Cornea"},{"key":"77_CR7","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1136\/bjo.83.4.384","volume":"83","author":"JD Nelson","year":"1999","unstructured":"Nelson JD: Much more than water. Br J Ophthalmol 1999, 83:384\u2013385.","journal-title":"Br J Ophthalmol"},{"key":"77_CR8","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1136\/bjo.86.2.181","volume":"86","author":"P Aragona","year":"2002","unstructured":"Aragona P, Papa V, Micali A, et al.: Long-term treatment with sodium hyaluronate-containing artificial tears reduces ocular surface damage in patients with dry eye. Br J Ophthalmol 2002, 86:181\u2013184.","journal-title":"Br J Ophthalmol"},{"key":"77_CR9","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1006\/exer.1998.0520","volume":"67","author":"JE Jumblatt","year":"1998","unstructured":"Jumblatt JE, Jumblatt MM: Regulation of ocular mucin secretion by P2Y2 nucleotide receptors in rabbit and human conjuctiva. Exp Eye Res 1998, 67:341\u2013346.","journal-title":"Exp Eye Res"},{"key":"77_CR10","first-page":"96","volume":"42","author":"T Fujihara","year":"2001","unstructured":"Fujihara T, Murakami T, Fujita H, et al.: Improvement of corneal barrier function by the P2Y(2) agonist INS365 in a rat dry eye model. Invest Ophthalmol Vis Sci 2001, 42:96\u2013100.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"77_CR11","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1097\/01.ico.0000133993.14768.a9","volume":"23","author":"J Tauber","year":"2004","unstructured":"Tauber J, Davitt WF, Bokosky JE, et al.: Double-masked, placebo-controlled safety and efficacy trial of diquafosol tetrasodium (INS365) ophthalmic solution for the treatment of dry eye. Cornea 2004, 23:784\u2013792. A study involving more than 1000 patients that demonstrates the benefit of diquafosol in dry eye.","journal-title":"Cornea"},{"key":"77_CR12","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1007\/978-1-4615-0717-8_180","volume":"506","author":"BR Yerxa","year":"2002","unstructured":"Yerxa BR, Mundasad M, Sylvester RN, et al.: Ocular safety of INS365 ophthalmic solution, a P2Y2 agonist, in patients with mild to moderate dry eye disease. Adv Exp Med Biol 2002, 506(Pt B):1251\u20131257.","journal-title":"Adv Exp Med Biol"},{"key":"77_CR13","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1111\/j.1601-0825.1997.tb00019.x","volume":"3","author":"NL Rhodus","year":"1997","unstructured":"Rhodus NL: Oral pilocarpine HCl stimulates labial (minor) salivary gland flow in patients with Sjogren\u2019s syndrome. Oral Dis 1997, 3:93\u201398.","journal-title":"Oral Dis"},{"key":"77_CR14","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1001\/archinte.159.2.174","volume":"159","author":"FB Vivino","year":"1999","unstructured":"Vivino FB, Al Hashimi I, Khan Z, et al.: Pilocarpine tablets for the treatment of dry mouth and dry eye symptoms in patients with Sjogren syndrome: a randomized, placebo-controlled, fixed-dose, multicenter trial. P92-01 Study Group. Arch Intern Med 1999, 159:174\u2013181. This is the largest of the studies demonstrating the benefit of pilocarpine tablets for sicca symptoms in SS.","journal-title":"Arch Intern Med"},{"key":"77_CR15","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.1136\/ard.2002.003889","volume":"62","author":"N Tsifetaki","year":"2003","unstructured":"Tsifetaki N, Kitsos G, Paschides CA, et al.: Oral pilocarpine for the treatment of ocular symptoms in patients with Sjogren\u2019s syndrome: a randomised 12 week controlled study. Ann Rheum Dis 2003, 62:1204\u20131207.","journal-title":"Ann Rheum Dis"},{"key":"77_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/030097401300232583","volume":"S115","author":"FB Vivino","year":"2001","unstructured":"Vivino FB: The treatment of Sjogren\u2019s syndrome patients with pilocarpine-tablets. Scand J Rheumatol Suppl 2001, S115:1\u20139.","journal-title":"Scand J Rheumatol Suppl"},{"key":"77_CR17","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/0306-3623(94)90021-3","volume":"25","author":"Y Iwabuchi","year":"1994","unstructured":"Iwabuchi Y, Masuhara T: Sialogogic activities of SNI-2011 compared with those of pilocarpine and McN-A-343 in rat salivary glands: identification of a potential therapeutic agent for treatment of Sjorgen\u2019s syndrome. Gen Pharmacol 1994, 25:123\u2013129.","journal-title":"Gen Pharmacol"},{"key":"77_CR18","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1001\/archinte.162.11.1293","volume":"162","author":"RS Fife","year":"2002","unstructured":"Fife RS, Chase WF, Dore RK, et al.: Cevimeline for the treatment of xerostomia in patients with Sjogren syndrome: a randomized trial. Arch Intern Med 2002, 162:1293\u20131300.","journal-title":"Arch Intern Med"},{"key":"77_CR19","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1002\/art.510","volume":"46","author":"D Petrone","year":"2002","unstructured":"Petrone D, Condemi JJ, Fife R, et al.: A double-blind, randomized, placebo-controlled study of cevimeline in Sjogren\u2019s syndrome patients with xerostomia and keratoconjunctivitis sicca. Arthritis Rheum 2002, 46:748\u2013754. This randomized, controlled study documents that cevimeline increases tear flow and improves symptoms in patients with SS.","journal-title":"Arthritis Rheum"},{"key":"77_CR20","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/j.ajo.2004.02.010","volume":"138","author":"M Ono","year":"2004","unstructured":"Ono M, Takamura E, Shinozaki K, et al.: Therapeutic effect of cevimeline on dry eye in patients with Sjogren\u2019s syndrome: a randomized, double-blind clinical study. Am J Ophthalmol 2004, 138:6\u201317.","journal-title":"Am J Ophthalmol"},{"key":"77_CR21","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1007\/BF00918149","volume":"12","author":"DI Yannopoulos","year":"1992","unstructured":"Yannopoulos DI, Roncin S, Lamour A, et al.: Conjunctival epithelial cells from patients with Sjogren\u2019s syndrome inappropriately express major histocompatibility complex molecules, La(SSB) antigen, and heat-shock proteins. J Clin Immunol 1992, 12:259\u2013265.","journal-title":"J Clin Immunol"},{"key":"77_CR22","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1097\/00003226-199811000-00002","volume":"17","author":"ME Stern","year":"1998","unstructured":"Stern ME, Beuerman RW, Fox RI, et al.: The pathology of dry eye: the interaction between the ocular surface and lacrimal glands. Cornea 1998, 17:584\u2013589.","journal-title":"Cornea"},{"key":"77_CR23","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1016\/j.ajo.2003.10.036","volume":"137","author":"SC Pflugfelder","year":"2004","unstructured":"Pflugfelder SC: Antiinflammatory therapy for dry eye. Am J Ophthalmol 2004, 137:337\u2013342.","journal-title":"Am J Ophthalmol"},{"key":"77_CR24","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1016\/S0161-6420(99)90171-9","volume":"106","author":"P Marsh","year":"1999","unstructured":"Marsh P, Pflugfelder SC: Topical nonpreserved methylprednisolone therapy for keratoconjunctivitis sicca in Sjogren syndrome. Ophthalmology 1999, 106:811\u2013816.","journal-title":"Ophthalmology"},{"key":"77_CR25","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1016\/S0002-9394(03)00326-X","volume":"136","author":"AM Avunduk","year":"2003","unstructured":"Avunduk AM, Avunduk MC, Varnell ED, Kaufman HE: The comparison of efficacies of topical corticosteroids and nonsteroidal anti-inflammatory drops on dry eye patients: a clinical and immunocytochemical study. Am J Ophthalmol 2003, 136:593\u2013602.","journal-title":"Am J Ophthalmol"},{"key":"77_CR26","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1097\/00003226-200003000-00005","volume":"19","author":"R Avisar","year":"2000","unstructured":"Avisar R, Robinson A, Appel I, et al.: Diclofenac sodium, 0.1% (Voltaren Ophtha), versus sodium chloride, 5%, in the treatment of filamentary keratitis. Cornea 2000, 19:145\u2013147.","journal-title":"Cornea"},{"key":"77_CR27","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1136\/ard.45.9.732","volume":"45","author":"AA Drosos","year":"1986","unstructured":"Drosos AA, Skopouli FN, Costopoulos JS, et al.: Cyclosporin A (CyA) in primary Sjogren\u2019s syndrome: a double blind study. Ann Rheum Dis 1986, 45:732\u2013735.","journal-title":"Ann Rheum Dis"},{"key":"77_CR28","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1001\/archopht.1989.01070020276038","volume":"107","author":"RL Kaswan","year":"1989","unstructured":"Kaswan RL, Salisbury MA, Ward DA: Spontaneous canine keratoconjunctivitis sicca. A useful model for human keratoconjunctivitis sicca: treatment with cyclosporine eye drops. Arch Ophthalmol 1989, 107:1210\u20131216.","journal-title":"Arch Ophthalmol"},{"key":"77_CR29","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1001\/archopht.120.3.330","volume":"120","author":"KS Kunert","year":"2002","unstructured":"Kunert KS, Tisdale AS, Gipson IK: Goblet cell numbers and epithelial proliferation in the conjunctiva of patients with dry eye syndrome treated with cyclosporine. Arch Ophthalmol 2002, 120:330\u2013337.","journal-title":"Arch Ophthalmol"},{"key":"77_CR30","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1097\/00003226-199311000-00008","volume":"12","author":"WJ Power","year":"1993","unstructured":"Power WJ, Mullaney P, Farrell M, Collum LM: Effect of topical cyclosporin A on conjunctival T cells in patients with secondary Sjogren\u2019s syndrome. Cornea 1993, 12:507\u2013511.","journal-title":"Cornea"},{"key":"77_CR31","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1001\/archopht.118.11.1489","volume":"118","author":"KS Kunert","year":"2000","unstructured":"Kunert KS, Tisdale AS, Stern ME, et al.: Analysis of topical cyclosporine treatment of patients with dry eye syndrome: effect on conjunctival lymphocytes. Arch Ophthalmol 2000, 118:1489\u20131496.","journal-title":"Arch Ophthalmol"},{"key":"77_CR32","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1002\/1097-4652(200009)184:3<400::AID-JCP15>3.0.CO;2-W","volume":"184","author":"TE Phillips","year":"2000","unstructured":"Phillips TE, McHugh J, Moore CP: Cyclosporine has a direct effect on the differentiation of a mucin-secreting cell line. J Cell Physiol 2000, 184:400\u2013408.","journal-title":"J Cell Physiol"},{"key":"77_CR33","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1097\/01.ico.0000133994.22392.47","volume":"24","author":"B Strong","year":"2005","unstructured":"Strong B, Farley W, Stern ME, Pflugfelder SC: Topical cyclosporine inhibits conjunctival epithelial apoptosis in experimental murine keratoconjunctivitis sicca. Cornea 2005, 24:80\u201385.","journal-title":"Cornea"},{"key":"77_CR34","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1111\/j.1755-3768.1994.tb02792.x","volume":"72","author":"K Gunduz","year":"1994","unstructured":"Gunduz K, Ozdemir O: Topical cyclosporin treatment of keratoconjunctivitis sicca in secondary Sjogren\u2019s syndrome. Acta Ophthalmol (Copenh) 1994, 72:438\u2013442.","journal-title":"Acta Ophthalmol (Copenh)"},{"key":"77_CR35","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1016\/S0161-6420(00)00035-X","volume":"107","author":"D Stevenson","year":"2000","unstructured":"Stevenson D, Tauber J, Reis BL: Efficacy and safety of cyclosporin A ophthalmic emulsion in the treatment of moderate-to-severe dry eye disease: a dose-ranging, randomized trial. The Cyclosporin A Phase 2 Study Group. Ophthalmology 2000, 107:967\u2013974.","journal-title":"Ophthalmology"},{"key":"77_CR36","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1016\/S0161-6420(99)00176-1","volume":"107","author":"K Sall","year":"2000","unstructured":"Sall K, Stevenson OD, Mundorf TK, Reis BL: Two multicenter, randomized studies of the efficacy and safety of cyclosporine ophthalmic emulsion in moderate to severe dry eye disease. CsA Phase 3 Study Group. Ophthalmology 2000, 107:631\u2013639. A large study presenting high-quality evidence in support of the benefit of cyclosporine ophthalmic emulsion.","journal-title":"Ophthalmology"},{"key":"77_CR37","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1089\/10807680260362696","volume":"18","author":"DS Small","year":"2002","unstructured":"Small DS, Acheampong A, Reis B, et al.: Blood concentrations of cyclosporin A during long-term treatment with cyclosporin A ophthalmic emulsions in patients with moderate to severe dry eye disease. J Ocul Pharmacol Ther 2002, 18:411\u2013418.","journal-title":"J Ocul Pharmacol Ther"},{"key":"77_CR38","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1136\/bjo.2003.026211","volume":"88","author":"BA Noble","year":"2004","unstructured":"Noble BA, Loh RS, MacLennan S, et al.: Comparison of autologous serum eye drops with conventional therapy in a randomised controlled crossover trial for ocular surface disease. Br J Ophthalmol 2004, 88:647\u2013652. This randomized, controlled study established that autologous serum drops are at least as effective as conventional therapy for dry eye.","journal-title":"Br J Ophthalmol"},{"key":"77_CR39","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1136\/bjo.83.4.390","volume":"83","author":"K Tsubota","year":"1999","unstructured":"Tsubota K, Goto E, Fujita H, et al.: Treatment of dry eye by autologous serum application in Sjogren\u2019s syndrome. Br J Ophthalmol 1999, 83:390\u2013395.","journal-title":"Br J Ophthalmol"},{"key":"77_CR40","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1007\/s11882-004-0077-2","volume":"4","author":"PD O\u2019Brien","year":"2004","unstructured":"O\u2019Brien PD, Collum LM: Dry eye: diagnosis and current treatment strategies. Curr Allergy Asthma Rep 2004, 4:314\u2013319.","journal-title":"Curr Allergy Asthma Rep"},{"key":"77_CR41","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1136\/bjo.87.10.1279","volume":"87","author":"S Shimmura","year":"2003","unstructured":"Shimmura S, Ueno R, Matsumoto Y, et al.: Albumin as a tear supplement in the treatment of severe dry eye. Br J Ophthalmol 2003, 87:1279\u20131283.","journal-title":"Br J Ophthalmol"},{"key":"77_CR42","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1067\/moe.2003.30","volume":"95","author":"AV Khurshudian","year":"2003","unstructured":"Khurshudian AV: A pilot study to test the efficacy of oral administration of interferon-alpha lozenges to patients with Sjogren\u2019s syndrome. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2003, 95:38\u201344.","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol Endod"},{"key":"77_CR43","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1097\/00003226-200203000-00001","volume":"21","author":"MC Tai","year":"2002","unstructured":"Tai MC, Cosar CB, Cohen EJ, et al.: The clinical efficacy of silicone punctal plug therapy. Cornea 2002, 21:135\u2013139.","journal-title":"Cornea"},{"key":"77_CR44","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1097\/00003226-200404000-00006","volume":"23","author":"A Sakamoto","year":"2004","unstructured":"Sakamoto A, Kitagawa K, Tatami A: Efficacy and retention rate of two types of silicone punctal plugs in patients with and without Sjogren syndrome. Cornea 2004, 23:249\u2013254.","journal-title":"Cornea"},{"key":"77_CR45","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1076\/orbi.22.1.29.14012","volume":"22","author":"J Murube","year":"2003","unstructured":"Murube J, Murube E, ChenZhuo L, Rivas L: Subcutaneous abdominal artificial tears pump-reservoir for severe dry eye. Orbit 2003, 22:29\u201340.","journal-title":"Orbit"},{"key":"77_CR46","doi-asserted-by":"publisher","first-page":"2903","DOI":"10.1002\/art.20472","volume":"50","author":"Y Hayashi","year":"2004","unstructured":"Hayashi Y, Ishimaru N, Arakaki R, et al.: Effective treatment of a mouse model of Sjogren\u2019s syndrome with eyedrop administration of anti-CD4 monoclonal antibody. Arthritis Rheum 2004, 50:2903\u20132910. Interesting and carefully conducted study showing the efficacy of a new form of treatment in an animal model of SS.","journal-title":"Arthritis Rheum"},{"key":"77_CR47","doi-asserted-by":"publisher","first-page":"4682","DOI":"10.1167\/iovs.03-0198","volume":"44","author":"S Nakamura","year":"2003","unstructured":"Nakamura S, Shibuya M, Saito Y, et al.: Protective effect of D-beta-hydroxybutyrate on corneal epithelia in dry eye conditions through suppression of apoptosis. Invest Ophthalmol Vis Sci 2003, 44:4682\u20134688.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"77_CR48","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1002\/1529-0131(200104)44:4<964::AID-ANR154>3.0.CO;2-5","volume":"44","author":"M Fleck","year":"2001","unstructured":"Fleck M, Zhang HG, Kern ER, et al.: Treatment of chronic sialadenitis in a murine model of Sjogren\u2019s syndrome by local fasL gene transfer. Arthritis Rheum 2001, 44:964\u2013973.","journal-title":"Arthritis Rheum"},{"key":"77_CR49","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1097\/00001665-200401000-00004","volume":"15","author":"JO Guerrissi","year":"2004","unstructured":"Guerrissi JO, Belmonte J: Surgical treatment of dry eye syndrome: conjunctival graft of the minor salivary gland. J Craniofac Surg 2004, 15:6\u201310.","journal-title":"J Craniofac Surg"}],"container-title":["Current Allergy and Asthma Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11882-005-0077-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11882-005-0077-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11882-005-0077-x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11882-005-0077-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,15]],"date-time":"2022-05-15T11:30:56Z","timestamp":1652614256000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11882-005-0077-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,7]]},"references-count":49,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2005,7]]}},"alternative-id":["77"],"URL":"https:\/\/doi.org\/10.1007\/s11882-005-0077-x","relation":{},"ISSN":["1529-7322","1534-6315"],"issn-type":[{"value":"1529-7322","type":"print"},{"value":"1534-6315","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,7]]}}}